International Patient Summary
Continuous Build
This is the Continuous Build of the HL7 CDA® R2 Implementation Guide International Patient Summary (will be incorrect/inconsistent at times).
See the Directory of the published standard.
This document contains: Standard for Trial Use International Patient Summary (2.00). The text materials belong to category cdaips.
International Patient Summary
STU Release 2 (Universal Realm)
© 2024 Health Level Seven International ® ALL RIGHTS RESERVED. The reproduction of this material in any form is strictly forbidden without the written permission of the publisher. HL7 and Health Level Seven are registered trademarks of Health Level Seven International. Reg. U.S. Pat & TM Off.
Use of this material is governed by HL7's IP Compliance Policy.
Important Notes
HL7 licenses its standards and select IP free of charge.If you did not acquire a free license from HL7 for this document, you are not authorized to access or make any use of it. To obtain a free license, please visit<a href="http://www.HL7.org/implement/standards/index.cfm" rel="noopener noreferrer nofollow">http://www.HL7.org/implement/standards/index.cfm</a>. If you are the individual that obtained the license for this HL7 Standard, specification or other freely licensed work (in each and every instance "Specified Material"), the following describes the permitted uses of the Material. A. HL7 INDIVIDUAL, STUDENT AND HEALTH PROFESSIONAL MEMBERS, who register and agree to the terms of HL7’s license, are authorized, without additional charge, to read, and to use Specified Material to develop and sell products and services that implement, but do not directly incorporate, the Specified Material in whole or in part without paying license fees to HL7. INDIVIDUAL, STUDENT AND HEALTH PROFESSIONAL MEMBERS wishing to incorporate additional items of Special Material in whole or part, into products and services, or to enjoy additional authorizations granted to HL7 ORGANIZATIONAL MEMBERS as noted below, must become ORGANIZATIONAL MEMBERS of HL7. B. HL7 ORGANIZATION MEMBERS, who register and agree to the terms of HL7's License, are authorized, without additional charge, on a perpetual (except as provided for in the full license terms governing the Material), non-exclusive and worldwide basis, the right to (a) download, copy (for internal purposes only) and share this Material with your employees and consultants for study purposes, and (b) utilize the Material for the purpose of developing, making, having made, using, marketing, importing, offering to sell or license, and selling or licensing, and to otherwise distribute, Compliant Products, in all cases subject to the conditions set forth in this Agreement and any relevant patent and other intellectual property rights of third parties (which may include members of HL7). No other license, sublicense, or other rights of any kind are granted under this Agreement. C. NON-MEMBERS, who register and agree to the terms of HL7’s IP policy for Specified Material, are authorized, without additional charge, to read and use the Specified Material for evaluating whether to implement, or in implementing, the Specified Material, and to use Specified Material to develop and sell products and services that implement, but do not directly incorporate, the Specified Material in whole or in part. NON-MEMBERS wishing to incorporate additional items of Specified Material in whole or part, into products and services, or to enjoy the additional authorizations granted to HL7 ORGANIZATIONAL MEMBERS, as noted above, must become ORGANIZATIONAL MEMBERS of HL7. Please see<a href="http://www.HL7.org/legal/ippolicy.cfm" rel="noopener noreferrer nofollow">http://www.HL7.org/legal/ippolicy.cfm</a>for the full license terms governing the Material. Ownership. Licensee agrees and acknowledges thatHL7 ownsall right, title, and interest, in and to the Materials. Licensee shalltake no action contrary to, or inconsistent with, the foregoing. Licensee agrees and acknowledges that HL7 may not own all right, title, and interest, in and to the Materials and that the Materials may contain and/or reference intellectual property owned by third parties (“Third Party IP”). Acceptance of these License Terms does not grant Licensee any rights with respect to Third Party IP. Licensee alone is responsible for identifying and obtaining any necessary licenses or authorizations to utilize Third Party IP in connection with the Materials or otherwise. Any actions, claims or suits brought by a third party resulting from a breach of any Third Party IP right by the Licensee remains the Licensee’s liability. Following is a non-exhaustive list of third-party terminologies that may require a separate license:
|
Primary Editor and Contributors
Primary Editor | Giorgio Cangioli, PhD | Primary Editor |
Primary Editor | Rob Hausam | Primary Editor |
Primary Editor | Dr Kai U. Heitmann | Primary Editor |
Primary Editor | François Macary | Primary Editor |
Contributor | Dr Philip Scott | Contributor |
Contributor | Dr Christof Geßner | Contributor |
Contributor | Dr Stefan Sabutsch | Contributor |
Contributor | Gary Dickinson | Contributor |
Contributor | Catherine Chronaki | Contributor |
Contributor | Dr Stephen Chu | Contributor |
Contributor | Didi Davis | Contributor |
Other Contributors | Alexander Berler (a.berler@gnomon.com.gr) ; Carina Seerainer (carina.seerainer@elga.gv.at); John Roberts (John.A.Roberts@tn.gov); Julie James (julie_james@bluewaveinformatics.co.uk); Mark Shafarman (mark.shafarman@earthlink.net); Fernando Portilla (fportila@gmail.com); Ed Hammond (william.hammond@duke.edu); Steve Kay (s.kay@histandards.net) | Other Contributors |
Introduction
AnInternational Patient Summary (IPS) documentis an electronic health record extract containing essential healthcare information about a subject of care. As specified in EN ISO 27269, it is designed for supporting the use case scenario for ‘unplanned, cross border care’, but it is not limited to it. It is intended to be international, i.e., to provide generic solutions for global application beyond a particular region or country.
The IPS dataset isminimal and non-exhaustive; specialty-agnostic and condition-independent; but still clinically relevant.
The IPS document is composed by a set of robust, well-defined and potentially reusable sets of core data items (indicated as IPS library in the figure below). The tight focus of the IPS on unplanned care is in this case not a limitation, but, on the contrary, facilitates their potential re-use beyond the IPS scope.
<img src="f784fd13-e44c-4a1c-84fd-13e44cfa1cc3.png" alt="f784fd13-e44c-4a1c-84fd-13e44cfa1cc3.png"/>
Figure 1: The IPS product and by-products
Purpose
The goal of this Implementation Guide is to specify how to represent in HL7 CDA the International Patient Summary (IPS). An alternative representation as templated HL7 FHIR R2 is also provided ( see the<a href="https://www.hl7.org/implement/standards/product_brief.cfm?product_id=483" rel="noopener noreferrer nofollow">hl7.org site</a>). The initial focus of the International Patient Summary (IPS) was the unplanned care across national borders. This specification can be used and be useful also in local applications and be supportive of planned care.
Scope
As specified in EN ISO 27269, the IPS dataset is a“minimal, non-exhaustive set of data elements required for the international patient summary”. A Patient Summary is defined by ISO/TR 12773-1:2009 as a “Health record extract comprising a standardized collection of clinical and contextual information (retrospective, concurrent, prospective) that provides a snapshot in time of a subject of care’s health information and healthcare.”
‘Minimal’ reflects the ideas of ‘summary’ and the need to be concise, but also alludes to the existence of a core set of data elements that all health care professionals can use; it is intended to be a specialty agnostic and condition independent set. It does not imply that all the items in the data set will be used in every summary. It is also possible to refine the extract from a record such that the content of the summary is more relevant to a particular condition (e.g. asthma) but no asthma-specific elements will be specified in this standard. The IPS Document or IPS can be extended by non-IPS standard condition-specific data. ‘Non-exhaustive’ recognizes that the ideal data set is not closed, and is likely to be extended, not just in terms of requirement evolution, but also pragmatically in instances of use.[EN ISO 27269].
Furthermore the scope of the IPS is global. Although this is a major challenge, this implementation guide takes various experiences and newer developments into account to address, as far as possible, global feasibility.
The following picture provides an overview of the current IPS content.
<img src="de56fc54-5c7f-491c-96fc-545c7f191ca7.png" alt="de56fc54-5c7f-491c-96fc-545c7f191ca7.png"/>
Figure 2: The IPS composition
Project Background and relationships with other projects
Details on the project background and relationships with other projects are available in the<a href="https://international-patient-summary.net/" rel="noopener noreferrer nofollow">IPS Website</a>.
Ballot Status of the Document
This Implementation Guide is STU with the intention to go normative.
Audience
The audience for this Implementation Guide includes:
Public
Citizens who want to carry or access their healthcare data for emergency or unplanned care purposes.
Regulatory
Policy makers such as healthcare payers or government agencies.
Healthcare information governance authorities and regulatory bodies.
Clinical
Healthcare providers that offer unscheduled and emergency care.
Healthcare providers that populate regional and national patient summaries.
Technical
Vendors of EHR systems for unplanned care management, personal health records and mobile health data applications.
System integrators.
Organizations that manage regional and national patient summaries.
Reading Publication Artifacts
A reading guide is available that explains the formalism used to express the publication artifacts, i.e. template meta data and template design. For convenience the guide is included in the appendix. (see section "How to read the table view for templates")
